



PRESS RELEASE

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

Crucell Announces 2004 Annual Results

Three-fold increase in revenue; significant reduction in cash burn; all product programs on target

Leiden, The Netherlands, January 24, 2005 – Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL) today announced its 2004 financial results. Revenue for the year ended December 31, 2004 was € 22.6 million (US\$ 30.9 million), representing a three-fold increase over the € 7.4 million (US\$ 10.1 million) reported in 2003. Cash burn was € 10.5 million (US\$ 14.3 million), less than half the cash burn of € 23.4 million (US\$ 32.0 million) recorded in 2003.

"The past year was our strongest in four years as a public company," noted Ronald H.P. Brus, MD, Crucell's President and Chief Executive Officer. "We achieved all key product development milestones, added several new partners, including sanofi aventis for the next-generation flu vaccine, broadened the licensing base for our cell-based manufacturing technology, and secured the involvement of Genentech in evaluating the STAR™ technology we acquired last year. All of this adds to our confidence that 2005 will provide significant opportunities for continued growth," he continued. "While maintaining our focus on our vaccine development, we plan to enter into further development initiatives as strategic opportunities arise. We will continue to seek potential strategic partners. In addition, we may seek other sources of external funding to finance these initiatives, which may include a modest capital raising."

Net loss in 2004 dropped to € 21.3 million (US\$ 29.1 million), compared to € 23.4 million (US\$ 31.9 million) in 2003, even allowing for a € 3.9 million (US\$ 5.3 million) increase in research and development expenses in line with the stepping up of core programs. At December 31, 2004 cash and cash equivalents stood at € 76.7 million (US\$ 104.7 million). These cash reserves, combined with ongoing revenues received from technology licensing contracts, selective external funding of programs and government grants, are considered adequate to fund the Company's existing vaccine development programs until break-even.

Crucell's Chief Financial Officer Leonard Kruimer commented: "Our financial results reflect the strength of the Company's business model. The key priority for 2005 is to bring our vaccine programs into clinical trials. Our financial management strategy,



proven ability to attract the best partners, and our careful control over cash burn make it clear we are ideally placed to bring our plans to fruition.”

Full Year 2004 Highlights

- **Influenza:** sanofi aventis (formerly Aventis Pasteur) and Crucell announced a strategic agreement to develop and commercialize novel PER.C6[®]-based influenza vaccines. Clinical trials are set to begin in the third quarter of 2005.
- **West Nile:** The State of Israel granted market authorization for a West Nile virus veterinary vaccine for geese developed by Crucell together with the Israeli Kimron Veterinary Institute; clinical trials of Crucell’s human West Nile virus vaccine are set to begin during the fourth quarter of 2005, with agreement reached with the Netherlands Vaccine Institute (NVI) for the manufacture of the clinical trial vaccine lots at the NVI’s new BSL-3 plant.
- **Malaria:** The National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (NIH) agreed to support the development of Crucell’s candidate Malaria vaccine. Monkey trial data announced in November 2004 showed excellent immune responses for Crucell’s AdVac[®]-based vaccine. Clinical trials are set to begin in 2006.
- **Ebola:** Experiments performed by the Vaccine Research Center (VRC) of the US National Institutes of Health (NIH) and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) demonstrated that a single dose of Crucell’s PER.C6[®]-based vaccine protects macaque monkeys from Ebola infection. Clinical trials are set to begin during the fourth quarter of 2005.
- **AIDS:** Crucell and the International AIDS Vaccine Initiative (IAVI) signed an exclusive license agreement to develop an AIDS vaccine based on Crucell’s AdVac[®] technology. Meanwhile, Merck’s PER.C6[®]-based HIV vaccine progressed to the next phase of clinical trials, thereby delivering a milestone payment to Crucell.
- **Rabies:** Crucell discovered an anti-rabies antibody product using its MAbstract[®] technology. The antibody product has proven effective in protecting hamsters against a lethal rabies challenge. Results of an evaluation of how to proceed with development will be announced in the second quarter of 2005.
- **SARS:** *The Lancet* medical journal published the results of a study demonstrating that a human monoclonal antibody, discovered with the use of Crucell’s MAbstract[®] technology and produced on the PER.C6[®] cell line, was able to effectively protect ferrets from SARS.
- **Tuberculosis:** Crucell and the Aeras Global TB Vaccine Foundation announced a new collaboration on the preclinical and clinical development of candidate tuberculosis (TB) vaccines. Proof-of-concept trial results will be announced in the second quarter of 2005.
- **ChromaGenics STAR[™]:** Crucell completed the acquisition of ChromaGenics B.V., adding its STAR[™] technology to Crucell’s protein production business. In a Genentech-funded joint evaluation program, Genentech and Crucell are currently



investigating whether STAR™ technology can increase the production yields of Genentech's proprietary systems.

- ***In the clinic:*** AME/Eli Lilly took the first antibody produced on PER.C6® technology to clinical trials in the US.
- ***DSM Milestone:*** Crucell and DSM Biologics achieved the first development milestone pertaining to their protein production collaboration, with the joint development program demonstrating industry-high yields;
- ***Licensing:*** New PER.C6® licensing deals were secured by the Crucell-DSM alliance with Biogen Idec, PanGenetics, Merus, Chiron, GSK, Synergenics LLC/Synco BioPartners Investments, MorphoSys and Micromet; Crucell signed further PER.C6® deals with NeoTropiX Inc, ML Laboratories, Wyeth, Vaxin, Merial, Edwards Life Sciences and Chiron.
- ***Midkap:*** Based on full-year 2004 turnover of shares, Crucell was selected by Euronext Indices B.V. as a candidate for inclusion in the Amsterdam Midkap (AMX) index.
- ***Intellectual property:*** Crucell brought its European patent position in line with its position in the US, securing European patents for PER.C6® and AdVac® technology. The first legal proceedings regarding infringement of the PER.C6® patent were subsequently launched against CEVEC. A further European Patent was added in January 2005 specifically relating to the application of PER.C6® for vaccines.
- ***Supervisory Board:*** Mr. Jan Pieter Oosterveld was appointed to Crucell's Supervisory Board by shareholders. Mr. Domenico Valerio, the Company's founder and former President & Chief Executive Officer, will continue to serve the Company in an advisory role with an emphasis on investor- and public – relations, and not as a member of the Supervisory Board. The Priority Share Foundation Crucell N.V. is pleased to nominate Mr. Arnold Hoevenaars RA as independent Supervisory Board member. The Company shall seek shareholders' approval for his appointment at the Company's next Annual General Meeting on June 2, 2005. Mr. Hoevenaars brings strong financial and accounting experience to the board. He is a chartered accountant and his previous positions include, among others, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/CEO of the Executive Board of Eureka B.V. and member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.
- ***Management:*** Mr. Ronald H.P. Brus MD was appointed as the new President, CEO and Chairman of the Management Board of Crucell at the Annual General Meeting of Shareholders on June 3, 2004. In addition, CSO Mr. Jaap Goudsmit MD PhD, and CFO Mr. Leonard Kruimer CPA, were appointed as members of the Company's Management Board.



Key Figures 2004
(€ million, except net loss per share)

	2004	% change	2003
Revenue	22.6	+ 205 %	7.4
Net loss	(21.3)	(9.0 %)	(23.4)
Net loss per share (basic and diluted)	(0.59)	(9.2 %)	(0.65)
Cash and cash equivalents on December 31	76.7	(12 %)	87.2

Details of the Financial Results Full Year 2004

Revenue

Crucell's revenue for the year 2004 was € 22.6 million (US\$ 30.9 million), compared to € 7.4 million (US\$ 10.1 million) in 2003. Licensing revenue in 2004 amounted to € 12.4 million (US\$ 17.0 million), representing a significant increase on the figure of € 4.8 million (US\$ 6.5 million) recorded in 2003.

Service fees increased to € 5.7 million (US\$ 7.8 million) in 2004 compared to € 0.4 million (US\$ 0.6 million) in 2003. This is a new line item added to the external reporting of Crucell's financial results and relates to work performed together with or on behalf of licensees or partners and funded by those licensees or partners.

Government grants and other revenues increased to € 4.5 million (US\$ 6.1 million) from € 2.2 million (US\$ 3.0 million). This growth largely reflects success in obtaining government grants to fund development programs.

Expenses and Results

Total research and development expenses in 2004 were € 26.1 million (US\$ 35.7 million), compared to € 22.3 million (US\$ 30.4 million) in 2003, the increase mainly relating to increased R&D staffing levels and laboratory expenses. This reflects the scaling up of the Company's core activity.

Selling, general and administrative (SG&A) expenses in 2004 were € 14.7 million (US\$ 20.1 million), compared to € 7.6 million (US\$ 10.4 million) in 2003. This increase was primarily driven by increases in non-cash expenses of € 4.8 million (US\$ 6.5 million). Non-cash expenses consisted of a € 3.1 million (US\$ 4.2 million) increase in warrant expenses as a result of share price increases, and a € 1.7 million (US\$ 2.3 million) non-cash increase in compensation expense. This is related to a one-time, non-cash reduction of compensation expenses in 2003. The remaining € 2.3



million (US\$ 3.1 million) increase in SG&A costs was due to increases in insurance premiums, advisory costs and compensation expenses over the year.

The net loss for the year 2004 amounted to € 21.3 million (US\$ 29.1 million), compared to a net loss of € 23.4 million (US\$ 31.9 million) in 2003. Net loss per share in 2004 was € 0.59 (US\$ 0.80), compared to € 0.65 (US\$ 0.89) in 2003.

Cash Flow and Cash Position

Total cash used in 2004 amounted to € 10.5 million (US\$ 14.3 million), compared to € 23.4 million (US\$ 32.0 million) in 2003.

Cash used in operating activities in 2004 amounted to € 5.4 million (US\$ 7.4 million), compared to € 22.1 million (US\$ 30.1 million) in 2003. This reduction was primarily a result of cash receipts on our increased revenues and receipt of trade accounts receivable, partly offset by a € 3.2 million (US\$ 4.4 million) reduction in deferred revenue on December 31, 2004 versus the previous year.

Cash used in investing activities in 2004 amounted to € 6.1 million (US\$ 8.3 million) compared to € 2.0 million (US\$ 2.9 million) in 2003. Investments in plant and equipment amounted to € 2.1 million (US\$ 2.9 million); the remaining € 4.0 million (US\$ 5.5 million) represents the acquisition cost of ChromaGenics B.V.

Crucell generated € 1.0 million (US\$ 1.4 million) in 2004 from financing activities, compared to € 0.7 million (US\$ 0.9 million) in 2003.

Crucell's cash and cash equivalents amount to € 76.7 million (US\$ 104.7 million) as of December 31, 2004.

Revenue and Results Fourth Quarter 2004

Crucell's revenue in the fourth quarter 2004 was € 6.5 million (US\$ 8.9 million), compared to revenue of € 3.0 million (US\$ 4.0 million) in the same quarter in 2003. Licensing revenues in the fourth quarter 2004 amounted to € 2.6 million (US\$ 3.6 million), compared to € 1.6 million (US\$ 2.1 million) in the fourth quarter 2003. Revenues in the fourth quarter consisted of upfront payments from new contracts as well as annual and other payments on existing contracts. Existing licenses with Cell Genesys and NatImmune were not renewed.

Government grants and other revenues amounted to € 1.9 million (US\$ 2.6 million) in the fourth quarter 2004, compared to € 1.3 million (US\$ 1.8 million) in the same period in 2003.

Crucell has in the past experienced significant fluctuations in quarterly revenues and expects to continue to experience such fluctuations in the future.



Research and development expenses increased in the fourth quarter 2004 to € 7.7 million (US\$ 10.5 million), compared to € 5.5 million (US\$ 7.5 million) in the fourth quarter of 2003. Selling, general and administrative expenses increased to € 4.4 million (US\$ 5.9 million) versus € 2.7 million (US\$ 3.7 million) in the same period 2003.

The net loss for the fourth quarter 2004 was € 6.8 million (US\$ 9.3 million), compared to € 6.4 million (US\$ 8.7 million) for the fourth quarter 2003.

NB: Euros converted to US Dollars at December 31, 2004 exchange rate of 1.36440.

Conference Call and Webcast

Crucell will conduct a conference call today, January 24, 2005, starting at 14:45 pm Central European Time (8:45 am US Eastern time). A presentation will be followed by a question and answer session. To participate in the conference call, please call one of the following toll-free numbers within 10 minutes prior to commencement:

866-328-4274 for the US;

0800-358-5261 for the UK;

0800-265-8531 for the Netherlands.

The event will be relayed by live audio webcast which can be accessed via the home page of Crucell's corporate website, www.crucell.com. The webcast will be available for replay from 18:00 pm CET and will be archived for four weeks thereafter.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6[®] technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6[®] technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.



For further information please contact:

Crucell N.V.

Leonard Kruimer
Chief Financial Officer
Tel. +31-(0)71-524 8722
l.kruimer@crucell.com

For Crucell N.V. in the USA:

Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com

Elizabeth Goodwin
Director IR & Corp. Communications
Tel. +31-(0)71-524 8718
e.goodwin@crucell.com

CRUCCELL N.V.
CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except per share data)

	3 months ended		12 months ended	
	December 31,		December 31,	
	2004	2003	2004	2003
REVENUES:				
License	€ 2,604	€ 1,563	€ 12,429	€ 4,800
Service fees	1,977	118	5,712	404
Government grants and other	1,923	1,285	4,481	2,220
Total revenues	6,504	2,966	22,622	7,424
COSTS AND EXPENSES:				
Research and development	7,660	5,507	26,112	22,285
Selling, general and administrative	4,355	2,723	14,704	7,605
Developed technology amortization	533	332	1,966	1,330
Stock based compensation	953	1,176	2,566	2,696
Total costs and expenses	13,501	9,738	45,348	33,916
LOSS FROM OPERATIONS	(6,997)	(6,772)	(22,726)	(26,492)
Interest income, net	319	406	1,503	2,143
Foreign currency gain/(loss)	(88)	15	(108)	(19)
Gain on sale of available for sale securities	-	-	-	982
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(6,766)	(6,351)	(21,331)	(23,386)
Provision for income taxes	-	-	-	-
NET LOSS	€ (6,766)	€ (6,351)	€ (21,331)	€ (23,386)
BASIC AND DILUTED NET LOSS PER SHARE:				
Net loss per share - basic and diluted	€ (0.18)	€ (0.18)	€ (0.59)	€ (0.65)
Weighted average shares outstanding - basic and diluted	36,708	36,005	36,383	35,921

CRUCELL N.V.
CONSOLIDATED STATEMENTS OF CASH FLOW
(amounts in thousands)

	12 months ended	
	December 31,	
	2004	2003
Operating activities		
Net loss	€ (21,331) €	(23,386)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	2,982	2,712
Loss on disposal of plant and equipment	-	460
Stock based employee compensation	2,566	2,696
Intangible amortization	1,966	1,330
Gain on sale of available for sale securities	-	(982)
Revenue recorded in exchange for equity instruments	-	(324)
Warrants to acquire ordinary shares for services	4,246	616
Change in operating assets and liabilities:		
Trade accounts receivable	7,527	(8,538)
Receivable from related parties and employees	438	239
Prepaid expenses and other current assets	(1,767)	(835)
Accounts payable	21	(320)
Accrued compensation and related benefits	242	(2,225)
Deferred revenue	(3,248)	7,787
Accrued liabilities	972	(1,285)
Net cash used in operating activities	(5,386)	(22,055)
Cash flow used in investing activities		
Purchase of developed technology	(4,017)	-
Purchase of plant and equipment	(2,114)	(3,448)
Proceeds from sale of plant and equipment	-	96
Proceeds from sale of available for sale securities	-	1,306
Net cash used in investing activities	(6,131)	(2,046)
Cash flow from financing activities		
Proceeds from the issuance of ordinary shares	1,409	310
Principal payments under capital lease obligation	(1,132)	(902)
Proceeds from sale and lease-back of plant and equipment	741	1,258
Net cash provided by financing activities	1,018	666
Net decrease in cash and cash equivalents	€ (10,499) €	(23,435)
Cash and cash equivalents at beginning of period	87,210	110,645
Cash and cash equivalents at end of period	76,711	87,210

CRUCCELL N.V.
CONSOLIDATED BALANCE SHEETS
(amounts in thousands)

	<u>December 31,</u> <u>2004</u>	<u>December 31,</u> <u>2003</u>
Assets		
Current assets:		
Cash and cash equivalents	€ 76,711	€ 87,210
Accounts receivable, net	2,020	9,547
Prepaid expenses and other current assets	5,425	3,658
Total current assets	<u>84,156</u>	<u>100,415</u>
Notes receivable from employees	224	662
Plant and equipment, net	10,465	11,333
Developed technology, net	<u>4,046</u>	<u>1,996</u>
Total assets	€ <u>98,891</u>	€ <u>114,406</u>
Liabilities and shareholders' equity		
Current liabilities:		
Accounts payable	€ 2,108	€ 2,087
Accrued compensation and related benefits	1,050	808
Short term portion of deferred revenues	6,373	5,371
Accrued and other liabilities	5,241	3,450
Total current liabilities	<u>14,772</u>	<u>11,716</u>
Long term liabilities		
Long term obligation under capital leases	1,385	2,597
Long term portion of deferred revenues	<u>4,198</u>	<u>8,448</u>
Total long term liabilities	5,583	11,045
Ordinary shares, €0.24 par value; 89,199,990 shares authorized; 36,873,421 and 36,006,324 shares issued and outstanding at December 31, 2004 and December 31, 2003 respectively		
	8,850	8,642
Additional paid in capital	349,167	340,678
Deferred compensation	(4,958)	(4,482)
Accumulated deficit	<u>(274,523)</u>	<u>(253,193)</u>
Total shareholders' equity	<u>78,536</u>	<u>91,645</u>
Total liabilities and shareholders' equity	€ <u>98,891</u>	€ <u>114,406</u>